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A stage IVA lung adenocarcinoma (cT3N2M1a)
harboring an epidermal growth factor receptor gene
(EGFR) mutation in exon 21 (L858R) was diagnosed in a
57-year-old woman, a never-smoker. The patient was
treated with erlotinib for 12 months and then with
cisplatin plus pemetrexed followed by pemetrexed for 8
months. At the time of progression, a repeat biopsy
showed a T790M missense mutation in exon 20 accom-
panied by an L858R mutation. The patient participated in
a phase I clinical trial of AZD9291 and was treated with a
dose of 160 mg. Notable shrinkage of her lung mass was
observed after two cycles of AZD9291, and this response
continued for 14 months. Eventually, she experienced
rapid progression of the disease along with aggravation
of her symptoms, including cough and dyspnea. A repeat
biopsy was performed because of the rapid progression,
and histologic analysis of her lung mass showed small cell
lung cancer (SCLC) that immunohistochemical staining
conﬁrmed as positive for CD56 (Fig. 1). Intriguingly, a
next-generation sequence showed persistence of the
L858R mutation and EGFR gene ampliﬁcation but loss of
the T790M mutation (Fig. 2 and Supplemental Fig. 1).
After two cycles of etoposide and carboplatin, the pa-
tient’s tumor was markedly smaller on a follow-up chest
computed tomography scan (Fig. 3) and her respiratory
symptoms also improved.
Case 2
Recurrent lung adenocarcinoma with lung-to-
lung metastasis developed in a 58-year-old woman, anever-smoker, 2 years after she had undergone cura-
tive surgery. Direct sequencing of her tumor showed
EGFR wild-type disease. The patient was treated with
erlotinib for 24 months as second-line therapy fol-
lowed by afatinib for 9 months. At the time of disease
progression, a repeat biopsy showed an exon 19 dele-
tion along with a T790M mutation. The patient also
participated in a phase I clinical trial of AZD9291
and was treated with a dose of 80 mg. Her disease
progressed after 18 months of treatment, and a repeat
biopsy specimen showed SCLC (see Fig. 1). The next-
generation sequence showed loss of the T790M muta-
tion but presence of an exon 19 deletion (see Fig. 2 and
Supplemental Fig. 1). The patient also achieved a par-
tial response to etoposide and carboplatin combination
therapy (Supplemental Fig. 2).
Discussion
SCLC transformation is one of the resistance mecha-
nisms associated with treatment with ﬁrst-generationJournal of Thoracic Oncology Vol. 11 No. 1: e1-e4
Figure 1. (A) Tissue section from the pleura of the patient in case 1 (hematoxylin and eosin stain, magniﬁcation 400) that
was obtained before AZD9291 treatment and shows metastatic adenocarcinoma. (B) Tissue section obtained from a lung of
the patient in case 1 and showing small cell carcinoma (hematoxylin and eosin stain, magniﬁcation 400). (C) Tissue sample
from the same lung (CD56 immunohistochemical stain, magniﬁcation 400); CD56-positive staining was obtained when the
patient’s disease progressed while she was receiving AZD9291 for 14 months. (D) Tissue section from a lung of the patient in
case 2 (hematoxylin and eosin stain, magniﬁcation 400) that was obtained before AZD9291 treatment and shows adeno-
carcinoma. (E) Tissue section from a lung of the patient in case 2 showing small cell carcinoma (hematoxylin and eosin stain,
magniﬁcation 400). (F) Tissue section from the same lung (CD56 immunohistochemical stain, magniﬁcation 400); CD56-
positive staining was obtained when the patient’s disease progressed while she was being given AZD9291 for 18 months.
e2 Ham et al Journal of Thoracic Oncology Vol. 11 No. 1EGFR tyrosine kinase inhibitors (TKIs), accounting for
10% of cases.1,2 AZD9291 (AstraZeneca) is an oral irre-
versible EGFR TKI with selectivity for activating EGFR
mutations and the T790M resistance mutation.3 A recent
phase I clinical study demonstrated that AZD9291
resulted in a response rate of 51% and progression-free
survival time of 9.6 months in EGFR T790M–positive
patients in whom resistance to previous EGFR TKIs had
developed.4 However, patients treated with third-
generation EGFR TKIs experience progression eventu-
ally. Recently, two cases of SCLC transformation during
treatment with the third-generation EGFR TKI rociletinib
were reported as being characterized by a resistance
mechanism5 that had not yet been described during
treatment with AZD9291. Acquired EGFR C797Smutation was thought to be one of the resistance
mechanisms associated with AZD9291 treatment.6
The two cases are the ﬁrst reported cases of SCLC
transformation during treatment with AZD9291.
Genomic study showed loss of the T790M mutation in
the presence of a preexisting EGFR mutation. We did not
ﬁnd any abnormalities of retinoblastoma (RB) genes in
either case. These results suggest that repeat biopsy is
also essential for patients whose disease progresses
while they are receiving a third-generation EGFR TKI so
that an appropriate treatment decision can be made
according to the diverse mechanisms of acquired resis-
tance. In the case of SCLC transformation, a favorable
response to combination chemotherapy with agents such
as etoposide and platinum can be expected.
Figure 2. In case 1, a next-generation sequence showed persistence of the L858R mutation (B) but loss of the T790M mutation
(A). In case 2, a next-generation sequence showed persistence of the exon 19 deletion (C) but loss of the T790M mutation (A).
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Figure 3. Computed tomography (CT) scans of the patient in case 1. (A) CT scan before AZD9291 treatment. Multiple pleural
nodules and a para-aortic lymph node were noted. (B) CT scan after 2 months of AZD9291 treatment. The extent of the
pleural nodules and para-aortic lymph node was decreased. (C) CT scan after 14 months of AZD9291 treatment. A huge left
upper lobe and hilar masses were noted. (D) CT scan after two cycles of etoposide and carboplatin chemotherapy. The huge
masses were markedly smaller.
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Note: To access the supplementary material accompa-
nying this article, visit the online version of Journal of
Thoracic Oncology at www.jto.org and at http://dx.doi.
org/10.1016/j.jtho.2015.09.013.
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